PDCD11 Stabilizes C‐MYC Oncoprotein by Hindering C‐MYC‐SKP2 Negative Feedback Loop to Facilitate Progression of p53‐Mutant Breast and Colon Malignancies
Advanced Science · 2025
DOI: 10.1002/advs.202502416 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Li Ding und 12 weiteren Autor:innen. Beteiligte Einrichtung: College of Bioscience and Biotechnology, Yangzhou University, Yangzhou, 225009, China. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins c-myc, Breast Neoplasms, Colonic Neoplasms, Tumor Suppressor Protein p53. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Natural Science Foundation of China, Natural Science Foundation of Jiangsu Province, Postgraduate Research & Practice Innovation Program of Jiangsu Province.
Abstract (Originalsprache)
C‐MYC is a proto‐oncoprotein whose dysregulation triggers tumorigenesis and tumor progression in ≈70% of cancer cases. It is presently demonstrated that aberrantly upregulated MYC is caused by the overexpressed and “extra‐nucleolar” PDCD11 in p53‐mutant breast and colon cancer cells, which is highly correlated to tumor progression, metastasis, and recurrence. In the nucleoplasm, PDCD11 binds to the TAD of C‐MYC to prevent SKP2, a transcriptional target of C‐MYC as well as one of the major E3 ligase components targeting C‐MYC, from interacting with and ubiquitinating C‐MYC in feedback. The ensuing stabilized C‐MYC activates downstream signaling to facilitate the cellular G1/S transition, proliferation, and migration. PDCD11 silencing restores SKP2‐mediated C‐MYC degradation, thereby remarkably suppressing tumor growth and metastasis in nude mice. These findings highlight PDCD11 as a novel C‐MYC partner and thereby offer a potential therapeutic rationale to challenge PDCD11‐mediated “pro‐stabilization” effect on C‐MYC, a widely considered “undruggable” target, to combat C‐MYC‐driven malignancies with p53 mutation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Bioscience and Biotechnology, Yangzhou University, Yangzhou, 225009, China.
- Department of General Surgery, Institute of General Surgery, Northern Jiangsu People's Hospital Affiliated to Yangzhou University, Yangzhou, 225001, China.
ORCID-Profile: Li Ding
Förderung
- Natural Science Foundation of China
- Natural Science Foundation of Jiangsu Province
- Postgraduate Research & Practice Innovation Program of Jiangsu Province
- Six Talent Peaks Project in Jiangsu Province
- Jiangsu Provincial Department of Science and Technology
- National Natural Science Foundation of China
Zitieren
APA
Ding, L., Ni, W., Ma, Y., Xu, L., Zhang, Z., Liao, K., Li, J., Mei, X., Wang, Z., Ge, H., Li, J., Tang, D., & Zhang, X. (2025). PDCD11 Stabilizes C‐MYC Oncoprotein by Hindering C‐MYC‐SKP2 Negative Feedback Loop to Facilitate Progression of p53‐Mutant Breast and Colon Malignancies. Advanced Science. https://doi.org/10.1002/advs.202502416
Vancouver
Ding L, Ni W, Ma Y, Xu L, Zhang Z, Liao K, et al. PDCD11 Stabilizes C‐MYC Oncoprotein by Hindering C‐MYC‐SKP2 Negative Feedback Loop to Facilitate Progression of p53‐Mutant Breast and Colon Malignancies. Advanced Science. 2025. doi:10.1002/advs.202502416
BibTeX
@article{Ding2025,
author = {Ding, Li and Ni, Wei and Ma, Yichao and Xu, Lin and Zhang, Zhiping and Liao, Kai and Li, Jingwen and Mei, Xinyu and Wang, Zhun and Ge, Huiqian and Li, Jiajia and Tang, Dong and Zhang, Xinyue},
title = {PDCD11 Stabilizes C‐MYC Oncoprotein by Hindering C‐MYC‐SKP2 Negative Feedback Loop to Facilitate Progression of p53‐Mutant Breast and Colon Malignancies},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202502416}
}
EUVIMED